- Home
- HOLOW vs ICUCW Comparison
HOLOW vs ICUCW Comparison
Compare HOLOW & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLOW | ICUCW |
|---|---|---|
| Founded | N/A | N/A |
| Country | China | United States |
| Employees | 64 | 18 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HOLOW | ICUCW |
|---|---|---|
| Price | $0.09 | $0.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 195.3K | N/A |
| Earning Date | 03-14-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,242,196.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 326.95 | N/A |
| 52 Week Low | $0.15 | N/A |
| 52 Week High | $0.18 | N/A |
Technical Indicators
Market Signals| Indicator | HOLOW | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 59.55 |
| Support Level | $0.09 | $0.02 |
| Resistance Level | $0.11 | $0.03 |
| Average True Range (ATR) | 0.02 | 0.00 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 8.76 | 62.22 |
Price Performance
Historical ComparisonAbout HOLOW MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.